SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CHANTAL Pharmaceutical

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Norrin Radd who wrote (1147)3/21/1998 11:44:00 AM
From: Charles A. King  Read Replies (1) of 1169
 
From the SEC Digest:

The Commission announced that on March 12 the U.S. District Court
for the Central District of California, entered a Final Consent
Judgment of Permanent Injunction, Disgorgement, and Civil Penalty
against David L. Holewinski of Pennsylvania for insider trading in
the securities of Chantal Pharmaceutical Corporation. The
Commission's complaint, filed on August 5, 1996, alleged that a
consultant to Chantal, Roger D. Wyatt, tipped Holewinski with
nonpublic information concerning The Upjohn Company's testing of
Chantal's Cyoctol compound, Chantal's then sole source of income.
The complaint also alleged that Holewinski then sold all of his and
his wife's Chantal shares prior to the announcement of the test
results by Chantal.

Without admitting or denying the Commission's allegations,
Holewinski consented to a permanent injunction from future
violations of the antifraud provisions of the federal securities
laws and agreed to pay a total of $61,245.41 in disgorgement,
prejudgment interest and civil penalties. [SEC v. Roger D. Wyatt and
David L. Holewinski, Civil Action No. 96-5399 TJH, Mcx, C.D. Cal.]
(LR-15676)

sec.gov
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext